Deltagen, Inc. provides drug discovery tools to the biopharmaceutical industry and the academic research community in the United States. The company licenses its inventory of knockout mouse lines and related phenotypic data. In addition, it offers target validation data in the areas of immunology and metabolic diseases. The company’s proprietary database, DeltaBase, provides information, based on knockout mouse studies, on gene function and validated gene targets for drug discovery. DeltaBase contains phenotypic data on 750 different knockout mouse lines. In addition to those 750 knockout mouse lines, Deltagen has approximately 150 additional knockout mouse lines that have not been characterized phenotypically. Deltagen also has approximately 450 knockout lines at the embryonic stem (ES) cell stage. The company’s DeltaOne product offers access to its portfolio of knockout mice and/or accompanying phenotypic data, as well as any corresponding intellectual property, on a gene-by-gene basis. The company’s customers and partners/collaborators include various pharmaceutical companies, such as GlaxoSmithKline plc; Merck & Co., Inc.; Pfizer, Inc.; Eli Lilly and Company; and Schering-Plough Research Institute. The company also sells its knockout mouse lines and related phenotypic data in Japan, China, and South Korea. History Deltagen, Inc. was founded in 1997.
deltagen inc (DGEN:OTC US)
1900 South Norfolk Street
San Mateo, CA 94403
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for DGEN.|
|View Industry Companies|
|Price/Cash Flow||--||Not Meaningful|
Sponsored Financial Commentaries
To contact DELTAGEN INC, please visit www.deltagen.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.